Showing results (31-40 of 156) with videos related to
Sort By:
Pageof 16
Frontiers in Molecular Biosciences|June 18, 2024
The role of HOTAIR in the modulation of resistance to anticancer therapyMonica Cantile, Valentina Belli, Giosuè Scognamiglio, et al.International Journal of Oncology|December 1, 2023
Endocrine nuclear receptors and long non‑coding RNAs reciprocal regulation in cancer (Review)Monica Cantile, Margherita Cerrone, Maurizio Di Bonito, et al.Journal of Cellular Physiology|October 27, 2018
Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small-cell lung cancer cellsMaria Rita Milone, Rita Lombardi, Maria Serena Roca, et al.Amino Acids|October 21, 2016
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostatCarmine Carbone, Elena Di Gennaro, Geny Piro, et al.Recent Patents on Anti-Cancer Drug Discovery|December 1, 2017
Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of StatinsFederica Iannelli, Rita Lombardi, Maria R Milone, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivoFrancesca Bruzzese, Elena Di Gennaro, Antonio Avallone, et al.Metabolomics : Official Journal of the Metabolomic Society|March 5, 2019
Effects of α-zearalenol on the metabolome of two breast cancer cell lines by 1H-NMR approachAnna Chiara Nittoli, Susan Costantini, Angela Sorice, et al.Journal of Cellular Physiology|June 11, 2011
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMTFrancesca Bruzzese, Alessandra Leone, Monia Rocco, et al.Molecular Oncology|August 9, 2016
Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotypeMaria Rita Milone, Biagio Pucci, Tommaso Colangelo, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 3, 2025
Drug-like molecules targeting androgen receptor's allosteric binding sites selected by augmented AI and high-throughput screening as antitumor agents against prostate cancerFrancesca Bruzzese, Federica Iannelli, Maria Serena Roca, et al.Pageof 16